Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1,…
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme’s Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Partnership unites Illumina’s leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for…
HarmonEyes Completes Acquisition of iFocus Health, Bringing AI-Powered Clarity to ADHD Treatment
Acquisition adds eye-tracking-based ADHD medication management tool to HarmonEyes’ growing human performance platform BETHESDA, Md., Dec. 10, 2025…
Lin Health Raises $11 Million Series A to Fuel Growth of Virtual Chronic Pain Recovery Platform
Oversubscribed round demonstrates strong investor confidence in Lin Health’s neuroscience-based approach to chronic pain DENVER, Dec. 9, 2025…
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
LAS VEGAS, Dec. 9, 2025 /PRNewswire/ — Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology…
FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi’s 15-Year Campaign to Cut Biologic Drug Costs
A Landmark Regulatory Shift Validates Professor Sarfaraz K. Niazi’s Vision to Make Biologics as Affordable as Generics CHICAGO,…
As Part of November’s Diabetes-related Eye Disease Month, Prevent Blindness Launches New Resources to Educate Public on the Effects Diabetes has on Vision
According to the study, “Prevalence of Diabetic Retinopathy in the US in 2021,” approximately one in four Americans…
NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits
PARAGON Study Confirms Sustained Efficacy and Safety of NEUROMARK® System in Allergic and Nonallergic Rhinitis Patients GALWAY, Ireland,…
Lilly’s Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer’s disease
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with…
Sleep Aids Market to Hit US$ 118.97 Billion by 2033, Growing at 7.8% CAGR
AUSTIN, Texas and TOKYO, Sept. 19, 2025 /PRNewswire/ — According to DataM Intelligence, the global sleep aids market…
In Vitro Diagnostics (IVD) Quality Control Market worth $2.15 billion by 2030 with 5.5% CAGR
DELRAY BEACH, Fla., Sept. 19, 2025 /PRNewswire/ — The global In Vitro Diagnostics Quality Control Market, valued at…
AAOS Updates Clinical Practice Guideline for the Management of Rotator Cuff Injuries
Updated guideline based on the latest evidence-based recommendations ROSEMONT, Ill., Aug. 28, 2025 /PRNewswire/ — The American Academy…